Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Receivables - Net: 2016-2024

Historic Receivables - Net for Zevra Therapeutics (ZVRA) over the last 9 years, with Dec 2024 value amounting to $10.5 million.

  • Zevra Therapeutics' Receivables - Net rose 116.19% to $16.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.8 million, marking a year-over-year increase of 116.19%. This contributed to the annual value of $10.5 million for FY2024, which is 39.52% down from last year.
  • As of FY2024, Zevra Therapeutics' Receivables - Net stood at $10.5 million, which was down 39.52% from $17.4 million recorded in FY2023.
  • Zevra Therapeutics' Receivables - Net's 5-year high stood at $17.4 million during FY2023, with a 5-year trough of $1.5 million in FY2021.
  • In the last 3 years, Zevra Therapeutics' Receivables - Net had a median value of $10.5 million in 2024 and averaged $12.1 million.
  • Per our database at Business Quant, Zevra Therapeutics' Receivables - Net crashed by 40.75% in 2021 and then skyrocketed by 443.13% in 2022.
  • Over the past 5 years, Zevra Therapeutics' Receivables - Net (Yearly) stood at $2.6 million in 2020, then slumped by 40.75% to $1.5 million in 2021, then spiked by 443.13% to $8.3 million in 2022, then spiked by 109.39% to $17.4 million in 2023, then crashed by 39.52% to $10.5 million in 2024.